FDA-Approved mRNA Flu Shot Has No CDC Recommendation While a Court Order Keeps the Vaccine Advisory Panel From Meeting

A Vaccine No One Will Recommend

Moderna's new flu shot cleared its biggest hurdle on August 5, 2026. The FDA gave full approval to mFlusiva, the first U.S. flu vaccine built on mRNA technology, for adults ages 50 to 64, and a conditional approval for adults 65 and older^[1][10]. In a late-stage trial, it outperformed a standard flu shot by about 27%^[1][10].

Seven weeks later, it still isn't on the CDC's list of recommended vaccines. This month the CDC posted that it will simply keep last year's flu guidance for the 2026-27 season, citing "legal uncertainties and inquiries"^[2]. The Associated Press called that a break with how the agency normally operates^[2]. A federal court order is the reason the CDC can't update that list — and the fight over who caused that order is the real story here.

Why FDA Approval Isn't the Finish Line

To understand the standstill, you need to understand what FDA approval actually does, and what it doesn't. FDA approval means a vaccine is safe and effective enough to be sold. It does not put a shot on the government's recommended list.

That second step belongs to a different body: the Advisory Committee on Immunization Practices, or ACIP. ACIP is a panel of outside experts that reviews each new vaccine and votes on who should get it^[8]. When the CDC adopts that vote, the vaccine becomes part of the official schedule that doctors, pharmacies and insurers actually follow^[8].

That gate matters because insurance coverage, pharmacy stocking and doctor recommendations all run through it. A vaccine can be fully approved by the FDA and still sit on the sidelines if ACIP never votes on it. That's exactly what's happening to mFlusiva right now.

So whoever controls ACIP controls which vaccines get used at scale. That's why the fight over the panel's makeup, not the vaccine itself, is what's freezing things.

The Panel That Hasn't Met Since March

In June 2025, Health Secretary Robert F. Kennedy Jr. fired all 17 sitting ACIP members and appointed his own picks^[8]. In January 2026, the reshaped panel helped cut the CDC's recommended childhood vaccine list from 17 vaccines to 11^[9]. The American Academy of Pediatrics and other medical groups, who had already sued over the firings, amended their case to challenge that cut too^[9].

On March 16, 2026, U.S. District Judge Brian E. Murphy ruled that Kennedy had likely broken federal procedure in rebuilding the panel^[3]. He found that the new appointees "appear distinctly unqualified"^[4]. His order paused the appointments of 13 of Kennedy's picks and froze every vote they'd cast^[3][4]. The Congressional Research Service says any ACIP changes made after June 11, 2025 are stayed by that order — meaning they have no legal effect for now^[8]. The panel hasn't met since^[1].

HHS appealed on April 29, 2026, and in June asked the First Circuit Court of Appeals to speed up its review^[5][7]. That appeal is still pending^[5][7]. Meanwhile, in April, HHS rewrote ACIP's charter — the document setting rules for who can serve — widening the eligibility criteria^[11][12]. Critics call that an attempt to route around the judge's order^[11]; HHS has defended the new charter as part of its broader push to open the panel to more perspectives^[12].

Two True Stories About Who's to Blame

Both sides in this fight can point to something that's simply true, and that's what makes it hard to referee. Kennedy's position is that a court, not his department, is what's currently stopping ACIP from doing its job. He told the appeals court that Murphy's order has left the committee unable to "review newly approved vaccines" or complete other work before flu season^[5]. An HHS spokesperson, Andrew Nixon, said the administration expects the ruling to be "overturned just like his other attempts to keep the Trump administration from governing"^[6]. On mFlusiva specifically, an HHS spokesperson said Kennedy believes mRNA vaccines "warrant heightened scientific scrutiny," and noted the shot already carries some of the FDA's strictest follow-up study requirements^[1]. It's true, as a factual matter, that the court order is the direct legal mechanism keeping the current panel from meeting^[3][4].

The plaintiff medical groups have an equally true counterpoint: the freeze exists because the judge found HHS likely skipped the legal process required to remake a federal advisory panel^[3][4]. In their reading, HHS could end the standstill on its own by appointing members through a lawful process, rather than waiting on the courts^[4]. They also argue that a body deciding which vaccines insurers cover and doctors give shouldn't be rebuilt overnight without proper vetting. It's also true, separately, that federal law sets out specific procedures for how advisory committee members should be chosen^[3].

Neither fact cancels the other out. The court order is what legally freezes ACIP today, and the court issued that order because it found HHS's process likely broke the law^[3][4]. That's the loop this story keeps circling: cause and consequence, both real, pointing at each other.

Caught in the Gap

Moderna, for its part, just wants its data taken on its own terms. The company points to mFlusiva's approval and its 27% effectiveness edge over standard shots, arguing a vaccine that cleared full FDA review shouldn't be held hostage to a fight over process^[1][10]. Without a CDC recommendation, though, the shot enters its first flu season without the backing that normally drives insurance coverage and pharmacy stocking, which could slow how quickly it reaches the adults it's approved for^[16][8].

Doctors, patients and state health programs are mostly bystanders here, and what they're asking for is simple: clear guidance. Some medical societies aren't waiting for the CDC and are recommending mFlusiva as an option on their own^[14][2]. The AP reported that federal officials only confirmed in late September that COVID shots could still be ordered through the Vaccines for Children program, a federal program that supplies free shots to eligible kids — one more example of basic questions sitting unanswered later than usual^[2].

Coverage of the fight split along familiar lines. AP's headline, "CDC vaccine policy recommendations grind to a halt under Health Secretary Kennedy," puts the cause on Kennedy, even though the immediate freeze comes from a court order the medical groups themselves sought^[2]. Fox News led not with the vaccine but with the judge, framing him as a "Biden-appointed judge twice shut down by SCOTUS" facing "activist" criticism^[17]. STAT's headline said the new ACIP charter aims to "empower Kennedy's allies," stating a motive in its own voice rather than attributing it to critics^[11]. Al Jazeera's coverage, by contrast, focused almost entirely on the FDA's earlier reversal on reviewing the vaccine at all, giving little space to the domestic legal fight^[13].

What Happens Next

As of August, ACIP's next meeting was tentatively set for October — but whether that happens depends entirely on the First Circuit^[1]. A ruling for HHS would restore Kennedy's appointees and reinstate the votes they'd already cast. A ruling against HHS would send the panel back to a slower, more traditional selection process — one the judge noted has historically taken close to two years to fill seats^[4].

Either way, flu season doesn't wait for the courts. For now, mFlusiva remains approved, effective by Moderna's own trial data, and absent from the one list that would put it in front of most American adults^[1][2].